NOAC
NOAC is a pharmaceutical drug with 7 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
5 of 5 finished
0.0%
0 ended early
2
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Single-stage Pulmonary Vein Isolation Combined With Percutaneous Left Atrial Appendage Occluder Implantation in Patients With Recent Onset Ischemic Stroke and Atrial Fibrillation
Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation
Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement
The Greek AntiPlatElet Atrial Fibrillation Registry.
Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation
Clinical Trials (7)
Single-stage Pulmonary Vein Isolation Combined With Percutaneous Left Atrial Appendage Occluder Implantation in Patients With Recent Onset Ischemic Stroke and Atrial Fibrillation
Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation
Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement
The Greek AntiPlatElet Atrial Fibrillation Registry.
Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation
NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH
This Study Observes the Use of New Oral Anticoagulants (NOACs) in Patients With a Heart Rhythm Disorder in Spain
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7